Biomedicines | Free Full-Text | Disease Mechanisms and Therapeutic Approaches in C9orf72 ALS-FTD | HTML
Sustained depletion of C9orf72 by ASO administration in the CNS does... | Download Scientific Diagram
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | PNAS
Molecular Mechanisms of Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion
Frontiers | The Development of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disorders | Genetics
Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia | SpringerLink
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | PNAS
Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. - Abstract - Europe PMC
New C9orf72 Biomarker Shows Promise | The ALS Association
Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia | SpringerLink
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
IJMS | Free Full-Text | Gene Therapy for ALS—A Perspective | HTML
C9orf72-mediated ALS and FTD: multiple pathways to disease | Nature Reviews Neurology
p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR) - ScienceDirect
Frontiers | The Development of C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disorders | Genetics
There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS - ScienceDirect
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD | Molecular Neurodegeneration | Full Text
Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | PNAS
New gene therapy targeting C9orf72-ALS begins Phase 1 clinical trial in the UK - MND Research Blog
Gene therapy for ALS: A review - ScienceDirect
C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD? | SpringerLink
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration | PNAS
Frontiers | C9ORF72: What It Is, What It Does, and Why It Matters | Cellular Neuroscience
